PDS Stock Recent News

Precision Drilling Corporation (NYSE:PDS ) Q1 2025 Earnings Conference Call April 24, 2025 1:00 PM ET Company Participants Lavonne Zdunich - Vice President of Investor Relations Carey Ford - Chief Financial Officer Kevin Neveu - President, Chief Executive Officer & Director Conference Call Participants Aaron MacNeil - TD Cowen Keith MacKey - RBC Capital Markets Waqar Syed - ATB Capital Markets John Gibson - BMO Capital Markets John Daniel - Daniel Energy Partners Aaron Rosenthal - JPMorgan Operator Good day and thank you for standing by. Welcome to the Precision Drilling Corporation 2025 First Quarter Results Conference Call and Webcast.

Precision Drilling (PDS) came out with quarterly earnings of $1.53 per share, missing the Zacks Consensus Estimate of $1.57 per share. This compares to earnings of $1.88 per share a year ago.

CALGARY, Alberta, April 23, 2025 (GLOBE NEWSWIRE) -- This news release contains “forward-looking information and statements” within the meaning of applicable securities laws. For a full disclosure of the forward-looking information and statements and the risks to which they are subject, see the “Cautionary Statement Regarding Forward-Looking Information and Statements” later in this news release. This news release contains references to certain Financial Measures and Ratios, including Adjusted EBITDA (earnings before income taxes, gain on investments and other assets, finance charges, foreign exchange, gain on asset disposals and depreciation and amortization), Funds Provided by (Used in) Operations, Net Capital Spending, Working Capital and Total Long-term Financial Liabilities. These terms do not have standardized meanings prescribed under International Financial Reporting Standards ( IFRS ) Accounting Standards and may not be comparable to similar measures used by other comp

PRINCETON, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that three abstracts on Versamune® HPV (PDS0101) have been accepted for presentation at the 2025 American Society of Clinical Oncology (“ASCO”) Annual Meeting, taking place May 30-June 3, 2025, in Chicago, Illinois.

Precision Drilling (PDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRINCETON, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that preclinical immune response data with a novel Infectimune® based flu vaccine will be featured in a symposium on universal influenza vaccines at the American Association of Immunologists' IMMUNOLOGY2025™ Annual Meeting, taking place May 3-7, 2025, in Honolulu, Hawaii.

NCI presentation to highlight IL-12 fused antibody drug conjugate during poster presentation PRINCETON, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that an abstract submitted by the National Cancer Institute (“NCI”) reporting clinical data on PDS01ADC, the Company's IL-12 fused antibody drug conjugate, has been accepted for presentation at the American Association for Cancer Research (“AACR”) Annual Meeting 2025, taking place April 25-30, 2025, in Chicago, Illinois.

CALGARY, Alberta, April 02, 2025 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (Precision or the Company) (TSX:PD; NYSE:PDS) announces today the filing of its Management Information Circular (the Circular) issued in connection with the 2025 Annual and Special Meeting of Shareholders (the Annual Meeting). A copy of the Circular can be downloaded from the Company's SEDAR+ profile at www.sedarplus.ca and the Company's EDGAR profile at www.sec.gov. The Circular is also available on Precision's website at www.precisiondrilling.com.

Initiated VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune ® HPV in HPV16-Positive Head and Neck Cancer

CALGARY, Alberta, March 26, 2025 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (Precision) intends to release its 2025 first quarter results after the market closes on Wednesday, April 23, 2025, and has scheduled a conference call to begin at 11:00 a.m. MT (1:00 p.m. ET) on the next day, Thursday, April 24, 2025.